OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
VDP56

Vidipha Central Pharmaceutical JSC

PharmaceuticalsVerified

Vidipha Central Pharmaceutical JSC maintains a capital structure with a debt-to-equity ratio of 0.46, indicating a relatively balanced approach to financing. The company's liquidity position is characterized by a current ratio of 1.88, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the operating cash flow is negative at -45,371,111,060 VND, which may raise concerns about its ability to fund operations without external financing. In terms of profitability, the company's return on equity is 2.19%, and its return on assets is 1.38%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The net income of 15,636,023,630 VND reflects a modest profit margin, which may indicate challenges in maintaining high gross margins or managing operating expenses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if market conditions in its primary operating region deteriorate. The growth trajectory of Vidipha Central Pharmaceutical JSC is not clearly defined in the available data, as there are no specific projections or historical revenue growth rates provided. The company's capital expenditure of -9,661,141,460 VND suggests a reduction in investment in new projects or facilities, which could impact future growth. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's free cash flow of 39,339,987,850 VND provides some flexibility, but the negative net cash position after subtracting total debt may necessitate careful management of cash reserves. Recent events, such as the latest actual revenue of 421,548,211,000 VND, suggest that the company is performing in line with analyst estimates. However, the absence of detailed filings or transcripts limits the ability to assess the company's strategic direction and operational performance in greater depth.

30-day price · VDP-4600.00 (-7.6%)
Low$53000.00High$60500.00Close$55900.00As of19 May, 00:00 UTC
Profile
CompanyVidipha Central Pharmaceutical JSC
TickerVDP.HM
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Vidipha Central Pharmaceutical JSC is a pharmaceutical company that generates revenue primarily through the production and sale of pharmaceutical products in Vietnam.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Vidipha Central Pharmaceutical JSC maintains a capital structure with a debt-to-equity ratio of 0.46, indicating a relatively balanced approach to financing. The company's liquidity position is characterized by a current ratio of 1.88, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the operating cash flow is negative at -45,371,111,060 VND, which may raise concerns about its ability to fund operations without external financing. In terms of profitability, the company's return on equity is 2.19%, and its return on assets is 1.38%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The net income of 15,636,023,630 VND reflects a modest profit margin, which may indicate challenges in maintaining high gross margins or managing operating expenses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if market conditions in its primary operating region deteriorate. The growth trajectory of Vidipha Central Pharmaceutical JSC is not clearly defined in the available data, as there are no specific projections or historical revenue growth rates provided. The company's capital expenditure of -9,661,141,460 VND suggests a reduction in investment in new projects or facilities, which could impact future growth. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's free cash flow of 39,339,987,850 VND provides some flexibility, but the negative net cash position after subtracting total debt may necessitate careful management of cash reserves. Recent events, such as the latest actual revenue of 421,548,211,000 VND, suggest that the company is performing in line with analyst estimates. However, the absence of detailed filings or transcripts limits the ability to assess the company's strategic direction and operational performance in greater depth.
Key takeaways
  • The company has a balanced capital structure with a debt-to-equity ratio of 0.46.
  • The return on equity and return on assets are below typical industry benchmarks.
  • Revenue is concentrated in a single business segment, increasing exposure to regional market risks.
  • The company's liquidity position is moderate, with a current ratio of 1.88.
  • Free cash flow is positive, but the negative operating cash flow may require external financing.
  • The company's growth trajectory is not clearly defined, and capital expenditure has decreased.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyVND
Revenue$223.20B
Gross profit$50.72B
Operating income$19.49B
Net income$15.64B
R&D
SG&A
D&A
SBC
Operating cash flow-$45.37B
CapEx-$9.66B
Free cash flow$39.34B
Total assets$1.14T
Total liabilities$422.48B
Total equity$713.14B
Cash & equivalents
Long-term debt$330.45B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$785.36B$69.91B$60.22B$38.12B
FY-3$1.01T$92.22B$73.55B-$18.72B
FY-2$1.02T$91.18B$80.22B$23.99B
FY-1$934.49B$84.24B$71.82B$42.91B
FY0$985.64B$83.70B$63.81B$18.06B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.03T$584.23B
FY-3$1.10T$626.59B$17.00B
FY-2$1.09T$731.98B$0.00
FY-1$1.13T$751.77B
FY0$1.12T$750.07B$60.00B
PeriodOCFCapExFCFSBC
FY-4-$34.49B-$23.85B$38.12B
FY-3$11.05B-$64.95B-$18.72B
FY-2$108.74B-$59.84B$23.99B
FY-1$34.49B-$13.38B$42.91B
FY0$238.23B-$20.96B$18.06B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$223.20B$19.49B$15.64B$39.34B
FQ-6$213.46B$16.84B$15.57B$12.75B
FQ-5$294.09B$27.68B$23.07B$37.18B
FQ-4$210.31B$17.44B$14.13B-$13.60B
FQ-3$264.72B$23.06B$18.23B$1.23B
FQ-2$358.64B$15.62B$11.99B$36.08B
FQ-1$191.58B$27.43B$19.53B-$5.49B
FQ0$195.92B$12.06B$11.92B$19.34B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.14T$713.14B
FQ-6$1.12T$734.09B
FQ-5$1.13T$751.77B
FQ-4$1.02T$756.26B
FQ-3$1.12T$723.18B
FQ-2$1.05T$750.21B
FQ-1$1.12T$750.07B$60.00B
FQ0$1.04T$761.99B$131.00B
PeriodOCFCapExFCFSBC
FQ-7-$45.37B-$9.66B$39.34B
FQ-6-$38.99B-$25.62B$12.75B
FQ-5$34.49B-$13.38B$37.18B
FQ-4-$36.43B-$25.62B-$13.60B
FQ-3$106.95B-$7.33B$1.23B
FQ-2$28.53B-$3.38B$36.08B
FQ-1$238.23B-$20.96B-$5.49B
FQ0-$18.49B$19.34B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$713.14B
Net cash-$330.45B
Current ratio1.9
Debt/Equity0.5
ROA1.4%
ROE2.2%
Cash conversion-2.9%
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricVDPActivity
Op margin8.7%2.4% medp25 -91.8% · p75 12.5%above median
Net margin7.0%1.2% medp25 -98.4% · p75 10.4%above median
Gross margin22.7%45.6% medp25 29.8% · p75 66.7%bottom quartile
CapEx / revenue-4.3%-5.2% medp25 -15.8% · p75 -1.7%above median
Debt / equity46.0%9.3% medp25 0.1% · p75 43.8%top quartile
Observations
IR observations
Last actual revenue421,548,211,000 VND
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:18 UTC#0c5c37ae
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 21:58 UTCJob: b2e3a66f